AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05414409
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is an oral medication that improves insulin sensitivity.
Trial: NCT06415227
Drug: Vericiguat
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The target dose of vericiguat is 10 milligrams once daily, which will be started at 2.5mg once daily and uptitrated every two weeks to reach the target dose. Dose modification will depend on mean sitting systolic blood pressure and the absence of symptoms indicative of hypotension. The intention of the protocol is to reach and maintain the target study drug dose after completion of uptitration. If the dose is temporarily interrupted, then resumption of study drug treatment and continued uptitration will be considered at any subsequent visit when the investigator feels it is medically appropriate. Vericiguat will be taken orally once daily at about the same time.
Trial: NCT05643534
Drug: Tenapanor 50 MG
RxNorm normalized name: tenapanor 50 MG
DrugBank: Tenapanor (DB11761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive tenapanor 50 mg BID (total of 100 mg daily)
Trial: NCT05643534
Drug: Tenapanor 25 mg bid
DrugBank: Tenapanor (DB11761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive tenapanor 25 mg BID (total of 50 mg daily)
Trial: NCT06440967
Drug: Fezolinetant
RxNorm normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT06440967
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05108558
Drug: CCH administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
Trial: NCT04956640
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous
Trial: NCT04956640
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous
Trial: NCT04956640
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous
Trial: NCT04956640
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT04956640
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT06006117
Drug: Mosunetuzumab + Lenalidomide
RxNorm normalized name: Mosunetuzumab
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~  * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~ * C2 to C12: 45 mg D1 28-days cycles~* Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)
Trial: NCT06006117
Drug: - Rituximab + Bendamustine (28-days cycles)
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~* Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6.
Trial: NCT06006117
Drug: - Rituximab + CHOP (21-days cycles)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * CHOP, IV standard dose from cycle 1 to 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)
Trial: NCT06448624
Drug: Ampicillin sulbactam 3 days
RxNorm normalized name: ampicillin / sulbactam
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin sulbactam 1.5 gram IV BID for 3 days after CIED implantation
Trial: NCT05551104
Drug: Oral Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of oral nifedipine to control postpartum hypertension.
Trial: NCT05551104
Drug: Oral Labetalol
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of oral labetalol to control postpartum hypertension.
Trial: NCT06429449
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.
Trial: NCT06429449
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An analog of the pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
Trial: NCT06429449
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use.
Trial: NCT05395351
Drug: rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (IV rt-PA)
Trial: NCT05651828
Drug: Vismodegib 150 MG Oral Capsule
RxNorm normalized name: Vismodegib 150 mg oral capsule
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
Trial: NCT05649137
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Trial: NCT05649137
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Trial: NCT06453681
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine is a potent α2 agonist. In our practice, dexmedetomidine is administered as an additive to regional anesthesia to improve the duration and quality of analgesia
Trial: NCT06352632
Drug: Standard-dose intravenous tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose intravenous tenecteplase (0.25 mg/kg body weight); one-time IV bolus injection soon after randomisation
Trial: NCT06352632
Drug: Low-dose intravenous tenecteplase
RxNorm normalized name: ethinyl estradiol
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose intravenous tenecteplase (0.18 mg/kg body weight); one-time IV bolus injection soon after randomisation
Trial: NCT06352632
Drug: NoNO-42
RxNorm normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NoNO-42 at weight-based dosing - 2.6 mg/Kg, administered as a single IV infusion with a 20-minute dosing duration
Trial: NCT06352632
Drug: Deferoxamine mesylate only
RxNorm normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days
Trial: NCT06352632
Drug: Colchicine only
RxNorm normalized name: Colchicine only product
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg of oral colchicine daily for 30 days
Trial: NCT06352632
Drug: Both deferoxamine mesylate and colchicine
RxNorm normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days
Trial: NCT06098105
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupivacaine
Trial: NCT04989816
Drug: Trastuzumab Deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) by intravenous infusion
Trial: NCT05902845
Drug: RD13-02 cell infusion
RxNorm normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML [Penmenvy]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T cells
Trial: NCT05716113
Drug: RD13-02 cell infusion
RxNorm normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML [Penmenvy]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T cells
Trial: NCT05438992
Drug: Bupivacaine 0.25% Preservative-Free Injectable Solution
RxNorm normalized name: BUPivacaine 0.25% preservative-free injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local anesthetic drug injection for postoperative pain
Trial: NCT05980559
Drug: Xeomin
RxNorm normalized name: Xeomin
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally (15 Units per muscle applied with 2 injections in each masseter muscle) (10 Units per muscle applied with 2 injections in each temporalis muscle)
Trial: NCT05362942
Drug: Venetoclax, Decitabine, Azacytidine, Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
Trial: NCT06342700
Drug: Rilzabrutinib crystalline form
RxNorm normalized name: Mesembryanthemum crystallinum whole extract
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Film coated tablet Route of administration:Oral
Trial: NCT06342700
Drug: Rilzabrutinib amorphous form
RxNorm normalized name: Rilzabrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Film coated tablet Route of administration:Oral
Trial: NCT05222646
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will receive single dose of 10mg of Metoclopramide intramuscularly
Trial: NCT00000234
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05353894
Drug: GNS561 oral tablets and capsules
RxNorm normalized name: vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two formulations and Two dosage will be compared
Trial: NCT04805736
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab 200 mg was given a few days after microwave ablation
Trial: NCT05335928
Drug: Abatacept plus
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Up to 4 study drug infusions at 10 mg/kg, IV~Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
Trial: NCT05484648
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone has been used to generally favorable results in peripheral nerve blocks as adjunct. Several studies have reported prolongation in the duration of ropivacaine, mepivacaine and bupivacaine when used in combination with dexamethasone.~Various mechanisms for the beneficial adjunctive effect of dexamethasone with Local Anesthetics (LA) have been proposed. One theory suggests that the improved analgesia and increased blockade duration is due to its anti-inflammatory properties. It also acts as a local vasoconstrictor and thus may act by reducing LA absorption. Furthermore, it also increases the activity of inhibitory potassium channels on nociceptive C-Fibers.
Trial: NCT05484648
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine is another promising drug being used as a local anaesthetic adjuvant in peripheral nerve blocks. It is an alpha-2 agonist, which has shown to have prolonged duration of postoperative analgesia when given with LA for peripheral nerve blocks with other beneficial effects such as reducing the opioid consumption. Alpha-2-agonists such as dexmedetomidine cause hyperpolarization-activated cation currents which inhibit the transmission of nociceptive fibers.
Trial: NCT06433713
Drug: Lidocaine IV
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: They received IV infusion of 2 mg/kg per hour of lidocaine starting with skin incision, which was maintained until skin closure. This was done using a syringe pump with the calculated amount of lidocaine added to 50 ml of normal saline infused at a rate of 50 ml/hr.
Trial: NCT00002381
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002381
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002381
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06515678
Drug: arm R - angiotensin receptor blockers ARB
RxNorm normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients with angiotensin receptor blocker (ARB) before or within 6 months following debulking surgery.~ARBs will be defined as any drugs from the Anatomical Therapeutic Classification C09CA with an indication for hypertension, including but not limited to: losartan, valsartan, irbesartan, candesartan or olmesartan medoxomil.
Trial: NCT05403476
Drug: FE 999049
RxNorm normalized name: Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
Trial: NCT04074096
Drug: Binimetinib Oral Tablet
RxNorm normalized name: binimetinib Oral Tablet
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients: binimetinib 45 mg PO BID.
Trial: NCT04074096
Drug: Encorafenib Oral Capsule
RxNorm normalized name: encorafenib Oral Capsule
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients: encorafenib 450 mg PO QD
Trial: NCT04074096
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients: pembrolizumab 200 mg IV Q3W
Trial: NCT05587699
Drug: CKD-843 A 45mg(Multiple dose)
RxNorm normalized name: sodium acetate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 Injection/3 Month, 3 times Injections
Trial: NCT05587699
Drug: CKD-843 A 45mg
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Injection
Trial: NCT05587699
Drug: CKD-843 A 55mg(Multiple dose)
RxNorm normalized name: sodium acetate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 Injection/3 Month, 3 times Injections
Trial: NCT05587699
Drug: CKD-843 A 55mg
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Injection
Trial: NCT06140732
Drug: camrelizumab and apatinib
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
Trial: NCT05113810
Drug: HCQ01
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
Trial: NCT05824559
Drug: ME-344
RxNorm normalized name: ME-344
DrugBank: ME-344 (DB13062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME-344 will be administered intravenously (IV)
Trial: NCT05824559
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered intravenously (IV)
Trial: NCT04551066
Drug: parsaclisib
RxNorm normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parsaclisib will be administered QD orally
Trial: NCT04551066
Drug: ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ruxolitinib will be administered BID orally
Trial: NCT06414577
Drug: Irinotecan Liposomal combined With Nituzumab
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan liposomal: 70mg/m2, ivgtt, d1; Nituzumab: 400 mg, igvtt, d1 One treatment cycle every two weeks for up to 8 cycles, or until disease progression, intolerable toxicity, death, and investigator judgment of no further benefit
Trial: NCT06397235
Drug: DEB-TACE+HAIC
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~RALOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; Raltitrexed, 3 mg/m2 infusion for 0.5 hour.
Trial: NCT06397235
Drug: DEB-TACE
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
Trial: NCT05157581
Drug: Methoxsalen Injection
RxNorm normalized name: Methoxsalen Injection
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
Trial: NCT05621174
Drug: Dexamfetamine
RxNorm normalized name: Dexamfetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magisterial Dexamfetamine